Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 15/20 | 1.00 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881897 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL29496311 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL919042 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL29577183 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL30292040 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL24217771 | 0.91 | CFTR (0.83) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1882597 | 0.91 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL1882593 | 0.91 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL1882595 | 0.91 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 | |
| SCHEMBL1880600 | 0.90 | CFTR (1.00) | CFTRNLRP3MEN1KMT2ADUSP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260138970-A1 | MODULATORS OF THE CALCIUM SIGNALING CASCADE | FONDAZIONE TELETHON ETS (IT) | 2026-05-21 | — | — | US | disclosed |
| US-12630521-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125686-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF CFTR | CYSTIC FIBROSIS FOUND (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4724470-A1 | AAV-CFTR VECTORS AND METHODS OF USING SAME | Children's Hospital Medical Center (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12583893-B2 | Use of esculentin and its derivatives for use in the treatment of cystic fibrosis | UNIVERSITÀ DEGLI STUDI DI ROMA LA SAPIENZA (IT) | 2026-03-24 | — | — | US | disclosed |
| WO-2009105234-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DEFECTS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE OR PROTEIN | COMBINATORX, INCORPORATED (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | US | disclosed |
| US-20070254050-A1 | Method for treatment of diarrhea-predominant irritable bowel syndrome | Jaguar Health, Inc. | 2007-11-01 | — | — | US | disclosed |
| US-7235573-B2 | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235573-B2 | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1549321-A4 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1549321-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| WO-2004028480-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583893-B2 | Use of esculentin and its derivatives for use in the treatment of cystic fibrosis | CFTR, SCNN1G, SCNN1B | CFTR 1/4885NLRP3 312/4885MEN1 2302/4885 |
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | CFTR 1/4885NLRP3 3828/4885MEN1 4240/4885 |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | CFTR 1/4885NLRP3 407/4885MEN1 2086/4885 |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | CFTR, TMEM205, TMEM33 | CFTR 1/4885NLRP3 444/4885MEN1 4413/4885 |
| US-20260138970-A1 | MODULATORS OF THE CALCIUM SIGNALING CASCADE | ITPR1, ITPR3, ITPR2 | CFTR 292/4885NLRP3 3673/4885MEN1 4085/4885 |
| US-20070254050-A1 | Method for treatment of diarrhea-predominant irritable bowel syndrome | SLC10A2, SLC6A1, SLC6A13 | CFTR 103/4885NLRP3 3746/4885MEN1 4356/4885 |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | CFTR, TMEM205, TMEM33 | CFTR 1/4885NLRP3 444/4885MEN1 4413/4885 |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | CFTR 543/4885NLRP3 1120/4885MEN1 4360/4885 |
| US-12630521-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | CFTR 1/4885NLRP3 3575/4885MEN1 4201/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | CFTR 1/4885NLRP3 4272/4885MEN1 4414/4885 |
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, CLCN2, SLC26A3 | CFTR 1/4885NLRP3 1771/4885MEN1 3165/4885 |
| US-20260125686-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF CFTR | CFTR, UPF1, RNGTT | CFTR 1/4885NLRP3 1294/4885MEN1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.